HomeCompareABIO vs PEP

ABIO vs PEP: Dividend Comparison 2026

ABIO yields 11.04% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $100.4K in total portfolio value· pulled ahead in Year 7
10 years
ABIO
ABIO
● Live price
11.04%
Share price
$28.80
Annual div
$3.18
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.5K
Annual income
$2,204.34
Full ABIO calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — ABIO vs PEP

📍 PEP pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABIOPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABIO + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABIO pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABIO
Annual income on $10K today (after 15% tax)
$938.54/yr
After 10yr DRIP, annual income (after tax)
$1,873.69/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, PEP beats the other by $50,720.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABIO + PEP for your $10,000?

ABIO: 50%PEP: 50%
100% PEP50/50100% ABIO
Portfolio after 10yr
$91.7K
Annual income
$32,040.01/yr
Blended yield
34.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

ABIO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.7
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABIO buys
0
PEP buys
0
No recent congressional trades found for ABIO or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABIOPEP
Forward yield11.04%3.63%
Annual dividend / share$3.18$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$41.5K$141.9K
Annual income after 10y$2,204.34$61,875.67
Total dividends collected$16.5K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: ABIO vs PEP ($10,000, DRIP)

YearABIO PortfolioABIO Income/yrPEP PortfolioPEP Income/yrGap
1$11,804$1,104.17$10,849$509.42+$955.00ABIO
2$13,849$1,218.11$11,969$750.47+$1.9KABIO
3$16,154$1,335.59$13,500$1,124.14+$2.7KABIO
4$18,740$1,455.97$15,680$1,721.66+$3.1KABIO
5$21,631$1,578.61$18,929$2,715.34+$2.7KABIO
6$24,848$1,702.89$24,023$4,450.80+$825.00ABIO
7← crossover$28,415$1,828.18$32,510$7,669.92$4.1KPEP
8$32,358$1,953.89$47,709$14,093.60$15.4KPEP
9$36,703$2,079.45$77,415$28,083.48$40.7KPEP
10$41,476$2,204.34$141,922$61,875.67$100.4KPEP

ABIO vs PEP: Complete Analysis 2026

ABIOStock

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Full ABIO Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this ABIO vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABIO vs SCHDABIO vs JEPIABIO vs OABIO vs KOABIO vs MAINABIO vs MOABIO vs PMABIO vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.